Cargando…
Recombinant BCG expressing the LTAK63 adjuvant induces increased early and long-term immune responses against Mycobacteria
The development of more effective vaccines against Mycobacterium tuberculosis has become a world priority. Previously, we have shown that a recombinant BCG expressing the LTAK63 adjuvant (rBCG-LTAK63) displayed higher protection than BCG against tuberculosis challenge in mice. In order to elucidate...
Autores principales: | Carvalho Dos Santos, Carina, Rodriguez, Dunia, Kanno Issamu, Alex, Cezar De Cerqueira Leite, Luciana, Pereira Nascimento, Ivan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7227645/ https://www.ncbi.nlm.nih.gov/pubmed/31665996 http://dx.doi.org/10.1080/21645515.2019.1669414 |
Ejemplares similares
-
Recombinant BCG expressing the LTAK63 adjuvant increased memory T cells and induced long-lasting protection against Mycobacterium tuberculosis challenge in mice
por: Marques-Neto, Lázaro Moreira, et al.
Publicado: (2023) -
Recombinant BCG expressing the LTAK63 adjuvant improves a short-term chemotherapy schedule in the control of tuberculosis in mice
por: Trentini, Monalisa Martins, et al.
Publicado: (2022) -
Recombinant BCG Expressing LTAK63 Adjuvant induces Superior Protection against Mycobacterium tuberculosis
por: Nascimento, Ivan P., et al.
Publicado: (2017) -
CRISPR/Cas9 Approach to Generate an Auxotrophic BCG Strain for Unmarked Expression of LTAK63 Adjuvant: A Tuberculosis Vaccine Candidate
por: Moraes, Luana, et al.
Publicado: (2022) -
Recombinant BCG-LTAK63 Vaccine Candidate for Tuberculosis Induces an Inflammatory Profile in Human Macrophages
por: dos Santos, Carina C., et al.
Publicado: (2022)